Adicet bio to present at upcoming investor conferences

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (car) t cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in september. details of the events are as follows: h.c. wainwright 24th annual global investment conference, september 12-14, 2022, new york, new york an on-d
ACET Ratings Summary
ACET Quant Ranking